Insight Venture Partners Files to Sell Additional $65.9M in Hinge Health Stock
HNGE has more than doubled off its 52-week low of $30.08.
Summary
A major institutional investor, Insight Venture Partners, has filed a Form 144 indicating an intent to sell an additional $65.9 million in Hinge Health stock, continuing a trend of significant share dispositions.
Key Events · Ownership and Investor Activity · HNGE
-
Intent to Sell Shares
Insight Venture Partners X, L.P., a 10% stockholder, has filed a Form 144 to sell 732,444 shares of Class A common stock, valued at approximately $65.9 million.
-
Ongoing Distribution by Major Investor
This filing is part of a series of recent Form 144s and Form 4s from Insight Venture Partners, indicating a continued reduction of their stake. The same entity has already sold $112.8 million worth of shares in the past three months.
-
Selling Near 52-Week Highs
The proposed sale occurs while Hinge Health's stock is trading near its 52-week high, suggesting the investor is capitalizing on favorable market conditions for their exit.
Analysis · HNGE · Technology
Insight Venture Partners, a 10% stockholder, has filed an intent to sell an additional $65.9 million worth of Hinge Health stock. This continues a pattern of significant distribution by this institutional investor, with over $112 million already sold in the past three months. The ongoing sales by a major holder, especially while the stock is trading near its 52-week high, could create an overhang on the share price.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HNGE was trading at $89.30 on NYSE in the Technology sector, with a market capitalization of approximately $6.9B. The 52-week trading range was $30.08 to $90.91. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.